Department of Ophthalmology, Third People's Hospital of Changzhou, Changzhou, China.
Department of Ophthalmology, Yixing People's Hospital, Yixing, China.
Br J Ophthalmol. 2018 Aug;102(8):1060-1065. doi: 10.1136/bjophthalmol-2017-311096. Epub 2017 Oct 31.
To evaluate the efficacy of oral spironolactone in patients with acute central serous chorioretinopathy (CSC).
This is a prospective, randomised controlled clinical study. Thirty patients with acute CSC were the participants, including 18 patients who were treated with spironolactone (40 mg orally, twice daily) for 2 months in the experimental group and 12 patients who received observation in the control group. Main outcome measures included the proportion of eyes achieving complete resolution of subretinal fluid (SRF), changes in central macular thickness (CMT), the height of SRF (SRFH), best corrected visual acuity (BCVA) and subfoveal choroidal thickness (SFCT). The follow-up period was 2 months.
Complete resolution of SRF was achieved in 55.6% (10/18) and 8.3% (1/12) of the eyes in the treatment group and the control group, respectively, at 2 months (p=0.018). The mean CMT and SRFH decreased significantly at each visit in both groups (p<0.05), and there was significant difference between the two groups at 2 months (p<0.05 and p<0.05, respectively). BCVA (in logarithm of the minimum angle of resolution; mean) improved in both groups at 2 months (p<0.05). In the treatment group, the mean baseline SFCT significantly decreased from 502.50±87.38 µm to 427.44±74.37 µm at 2 months (p<0.01), while the change from baseline (from 480.33±102.38 µm to 463.75±100.63 µm) was not significant in the control group (p=0.195). But the differences between the two groups in BCVA and SFCT were not significant.
Oral spironolactone is more effective with a faster absorption of SRF than observations. It is a promising treatment for acute CSC.
ChiCTR-IPR-16008428, Results.
评估口服螺内酯治疗急性中心性浆液性脉络膜视网膜病变（CSC）的疗效。
这是一项前瞻性、随机对照的临床研究。30 例急性 CSC 患者为研究对象，其中实验组 18 例患者接受螺内酯（40mg 口服，每日 2 次）治疗 2 个月，对照组 12 例患者接受观察。主要观察指标包括视网膜下液（SRF）完全消退的眼比例、中心黄斑厚度（CMT）变化、SRF 高度（SRFH）、最佳矫正视力（BCVA）和中心凹下脉络膜厚度（SFCT）。随访时间为 2 个月。
治疗组和对照组在第 2 个月时 SRF 完全消退的眼比例分别为 55.6%（10/18）和 8.3%（1/12）（p=0.018）。两组在每次随访时的 CMT 和 SRFH 均显著降低（p<0.05），且在第 2 个月时两组间差异有统计学意义（p<0.05 和 p<0.05）。两组在第 2 个月时 BCVA（以最小角分辨率的对数表示；均值）均提高（p<0.05）。治疗组的平均基线 SFCT 从 502.50±87.38µm 显著降低至 2 个月时的 427.44±74.37µm（p<0.01），而对照组从 480.33±102.38µm 至 463.75±100.63µm 的变化不显著（p=0.195）。但两组在 BCVA 和 SFCT 方面的差异无统计学意义。
口服螺内酯治疗急性 CSC 的效果优于观察，SRF 吸收更快。它是一种有前途的急性 CSC 治疗方法。
ChiCTR-IPR-16008428，结果。
